Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

161. Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention Full Text available with Trip Pro

of this study was to assess the safety of EBUS-TBNA in patients with lung cancer who underwent PCI within one year.We retrospectively reviewed the medical records of 24 patients who underwent EBUS-TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural-related complications were assessed as secondary outcomes.The coronary artery diseases requiring PCI were (...) Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim

2018 Thoracic cancer

162. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis Full Text available with Trip Pro

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder (...) and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.© 2018 The Authors. Thoracic Cancer

2018 Thoracic cancer

163. Comparison between computed tomography‐guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non‐small cell lung cancer Full Text available with Trip Pro

Comparison between computed tomography‐guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non‐small cell lung cancer The study was conducted to investigate the effectiveness and cost of computed tomography (CT)-guided percutaneous microwave ablation (MWA) and thoracoscopic lobectomy for stage I non-small cell lung cancer (NSCLC).We retrospectively analyzed the data of 46 and 85 patients with stage I NSCLC treated with CT-guided percutaneous MWA or thoracoscopic (...) hospital stay and lower cost, thus should be considered a better option for patients with severe cardiopulmonary comorbidity and patients unwilling to undergo surgery.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

164. Microarray expression profile of long non‐coding RNAs in human lung adenocarcinoma Full Text available with Trip Pro

Microarray expression profile of long non‐coding RNAs in human lung adenocarcinoma Long non-coding RNAs (lncRNAs) participate in many biological dynamics and play significant roles in gene regulation. LncRNA expression is altered in many cancers; however, the expressions and functions of lncRNA genes in lung adenocarcinoma (LAD) remain unknown.LncRNA and messenger RNA (mRNA) expression in LAD without lymphatic metastasis versus paired adjacent non-tumor (ANT) lung tissues and LAD with versus (...) . The expression patterns of selected lncRNAs (LINC00113, AC005009.1, ARHGAP22-IT1, AC009411.1, SRGAP3-AS2, EGFEM1P, FAM66E, and HLA-F-AS1) were consistent with microarray data. Differentially expressed mRNA genes were enriched in crucial Gene Ontology terms and pathways.Our results revealed differentially expressed lncRNAs in LAD, suggesting lncRNAs may be potential indicators for LAD diagnosis and therapy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons

2018 Thoracic cancer

165. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR Full Text available with Trip Pro

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKIs (...) of 177 TKI and 22 CCRT patients and found no statistically significant difference in overall (adjusted hazard ratio of death 0.71, 95% confidence interval 0.34-1.47) or lung cancer-specific survival (hazard ratio 0.65, 95% confidence interval 0.31-1.35). The results of most additional analyses were insignificant.In this population-based study from Taiwan with limited case numbers, no statistical difference in the survival outcomes of patients with clinical stage IIIb LA-mEGFR treated with either EGFR

2018 Thoracic cancer

166. Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy Full Text available with Trip Pro

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy Recombinant human endostatin (rh-endostatin) plus standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients has shown improved efficacy; however, it is unclear whether it is effective and safe when added to pemetrexed/cisplatin and used as maintenance (...) The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

167. From focal pulmonary pure ground‐glass opacity nodule detected by low‐dose computed tomography into invasive lung adenocarcinoma: A growth pattern analysis in the elderly Full Text available with Trip Pro

From focal pulmonary pure ground‐glass opacity nodule detected by low‐dose computed tomography into invasive lung adenocarcinoma: A growth pattern analysis in the elderly Elderly patients are under-represented in studies of pure ground-glass opacity (pGGO) nodules; thus, this study analyzed the growth pattern and clinical outcomes of pGGO nodules in the elderly in order to help make treatment decisions.We retrospectively reviewed patients aged over 60 years with screening-detected (...) compared to increased size alone (100% vs. 44.4%; P = 0.005).pGGO nodules had an indolent growth pattern and good prognosis in our patient sample, even after the appearance of a solid portion. Therefore, minimally invasive surgery after the development of a solid component may be an option for the elderly.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

168. ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report Full Text available with Trip Pro

ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report Distant metastases of pulmonary adenocarcinoma are regularly observed in the bones, brain, adrenal gland, and liver, but rarely in the breast or cervix. In this report, we describe a novel case of concurrent cervix and breast metastases from lung adenocarcinoma, with ALK rearrangements that were strongly consistent between the primary and metastatic cancers. A 44-year-old Chinese woman (...) metastases from lung adenocarcinoma. We conclude that physicians should consider that metastases may invade the breast and cervix uteri when making a diagnosis.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

169. Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant Full Text available with Trip Pro

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant Common gene fusion of the ALK gene is fusion of the ALK tyrosine kinase area and the 5'end of EML4. Seventeen EML4-ALK fusion variants have been reported. Herein, we report a novel EML4-ALK variant detected by next-generation sequencing in a 36-year-old female lung adenocarcinoma patient who experienced disease progression after six months of alectinib treatment. Second generation sequencing revealed (...) an EML4-ALK fusion variant in which intron 19 of EML4 was fused to exon 20 of ALK. This is the first case of EML4-ALK (E19: A20) fusion to be reported. Alectinib may show unsatisfactory therapeutic effects for this kind of ALK fusion.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

170. Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer Full Text available with Trip Pro

Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer Although phase III trials have shown improved overall and progression-free survival (PFS) using nivolumab compared to docetaxel in patients with non-small-cell lung cancer, the progressive disease ratio of nivolumab is higher than docetaxel. Furthermore, nonconventional response patterns of nivolumab make it difficult to determine (...) -cell lung cancer who were treated with nivolumab. The stratified data of each marker obtained during four weeks after nivolumab treatment were evaluated by Cox proportional hazards regression to verify the differences in PFS.One and four patients experienced progressive disease within two and four weeks, respectively. Therefore, 29 and 26 patients were analyzed two and four weeks after nivolumab administration, respectively. The results showed that the NLR after four weeks could predict PFS

2018 Thoracic cancer

171. Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series Full Text available with Trip Pro

Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series The combination of PD-1 inhibitors and cytotoxic drugs is reported to enhance anti-tumor activity in non-small cell lung cancer; however, the underlying synergistic mechanisms remain uncertain. This retrospective case series was designed to investigate objective response (...) the overall response rate to 62.5% (95% confidence interval [CI] 34.4-90.6%; P = 0.004) and median progression-free survival to six months (95% CI 4.6-7.4; P = 0.016), compared to nivolumab alone and preceding chemotherapy. The response to salvage chemotherapy was not associated with tumor PD-L1 expression. A partial response was achieved in four cases with ≤ 5% and ≤ 2.9 cells/mm2 of PD-1+ immune cells, whereas stable disease and progressive disease were observed in three cases with ≥ 30% and ≥ 12.7

2018 Thoracic cancer

172. Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study Full Text available with Trip Pro

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study Previous studies have shown amrubicin (AMR) to be an effective second-line treatment option for small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC has not been sufficiently evaluated.The medical records of elderly patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed (...) months; P = 0.004) were significantly longer in patients with sensitive relapse than those with refractory relapse. The frequency of grade 3 or higher neutropenia was high (n = 18, 58%), while febrile neutropenia was only observed in five patients (16%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed.AMR may be a feasible and effective regimen for elderly patients with relapsed SCLC.© 2018 The Authors. Thoracic Cancer published

2018 Thoracic cancer

173. Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy Full Text available with Trip Pro

of apatinib for the treatment of advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.We retrospectively analyzed the data of 34 patients (11 with squamous carcinoma and 23 with adenocarcinoma) who were treated with apatinib alone in a daily oral dose of 250 mg in the second-line or third-line setting from January 2016 to July 2017. The primary endpoint was progression-free survival (PFS).EGFR mutation or amplification was detected in 15 patients. The median PFS (...) Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), has proven to be effective and safe for treating patients with advanced gastric cancer after second-line chemotherapy failure. As VEGFR-2 targeted therapy has made encouraging progress for the treatment of a broad range of malignancies, we explored the efficacy and safety

2018 Thoracic cancer

174. MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1 Full Text available with Trip Pro

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1 The five-year survival rate of non-small cell lung cancer (NSCLC) patients is very low. MiR-873 is involved in the growth, metastasis, and differentiation of tumors. Herein, we determined the target gene and influence of miR-873 in NSCLC.MiRanda and Targetscan websites were used to predict the target gene of miR-873 in NSCLC. Luciferase activity (...) . These results indicate that miR-873-GLI1 signaling is involved in gefitinib resistance in NSCLC.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

175. BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer Full Text available with Trip Pro

BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer 30234143 2018 11 14 2331-4737 5 7-8 2018 Jul Oncoscience Oncoscience BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer. 218-219 10.18632/oncoscience.455 Lochmann Timothy L TL Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Bouck Ynes M YM Anthony Faber: Philips Institute for Oral (...) Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Faber Anthony C AC Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. eng Journal Article 2018 08 14 United States Oncoscience 101636666 2331-4737 BCL-2 apoptosis SCLC targeted therapy CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 06 13 2018 06 19

2018 Oncoscience

176. MiR‐520b restrains cell growth by targeting HDAC4 in lung cancer Full Text available with Trip Pro

MiR‐520b restrains cell growth by targeting HDAC4 in lung cancer MicroRNAs (miRNAs) function as tumor promoting or tumor suppressing factors in many cancers. MiR-520b contributes to progression in head-neck and liver cancers, spinal osteosarcoma, and glioma; however, the association of miR-520b with lung cancer progression remains unknown. In this investigation, we explore the effect of miR-520b targeting HDAC4 on lung cancer growth.The regulation of miR-520b or its inhibitor on HDAC4 (...) decrease in HDAC4 expression was observed in lung cancer A549 cells treated with different doses of miR-520b. The miR-520b inhibitor enhanced HDAC4 expression in lung cancer cells. Bioinformatics predicted the targeting of miR-520b on HDAC4. MiR-520b directly targeted the 3' untranslated region of HDAC4. The introduction of miR-520b obviously inhibited cell proliferation in vitro. Anti-miR-520b was capable of accelerating lung cancer cell proliferation; however, HDAC4 knockdown destroyed anti-miR-520b

2018 Thoracic cancer

177. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy Full Text available with Trip Pro

Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy While there is growing interest in the correlation between chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer, very few studies have examined the interaction between COPD and small cell lung cancer (SCLC). Therefore, the aim of this study was to examine the impact of COPD on the survival of patients with SCLC.The medical records (...) = 0.581), whereas the median PFS rates were 6.65 and 6.57 months, respectively (log-rank test, P = 0.559). Multivariate analysis identified Eastern Cooperative Oncology Group performance status ≥ 2 and extensive-stage SCLC as independent risk factors for shorter OS; however, coexisting COPD was not a predictor of survival.Although over half of the SCLC patients receiving chemotherapy had COPD, coexisting COPD had no impact on the survival of patients with SCLC.© 2018 The Authors. Thoracic Cancer

2018 Thoracic cancer

178. Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? Full Text available with Trip Pro

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? 30116594 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? e000421 10.1136/esmoopen-2018-000421 Pirker Robert R Department of Medicine I, Medical University of Vienna, Vienna, Austria. eng Editorial 2018 08 10 England ESMO Open 101690685 2059-7029 (...) PD-l1 biomarker immunotherapy predictive factor prognosis Competing interests: RB received honoraria from Merck Sharp Dohme for serving as a member of the Data Monitoring Committee of pembrolizumab trials in lung cancer. 2018 07 16 2018 07 17 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116594 10.1136/esmoopen-2018-000421 esmoopen-2018-000421 PMC6088342 N Engl J Med. 2015 Oct 22;373(17):1627-39 26412456 N Engl J Med. 2018 Jun 14;378(24):2288-2301 29863955 J Thorac Oncol. 2017 Feb;12(2

2018 ESMO open

179. Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the “no fly” zone Full Text available with Trip Pro

Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the “no fly” zone Stereotactic body radiotherapy (SBRT) has emerged as a highly effective technique to treat medically inoperable non-small cell lung cancer (NSCLC). Doses must be chosen carefully when treating central lesions because of the potential for significant toxicity. This study reviews the outcomes of a cohort of patients with central lung tumors treated with SBRT.We (...) fraction regimens. BED10 < 72 predicted disease progression, highlighting the importance of choosing an effective dose fractionation scheme, which must in turn be balanced with potential toxicity.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

180. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Full Text available with Trip Pro

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Broad-based genomic sequencing is being used more frequently for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the association between broad-based genomic sequencing and treatment selection or survival among patients with advanced NSCLC in a community oncology setting.To compare clinical outcomes (...) ]; P = .40) vs unmatched cohort (hazard ratio, 0.69 [95% CI, 0.62 to 0.77]; log-rank P < .001).Among patients with advanced non-small cell lung cancer receiving care in the community oncology setting, broad-based genomic sequencing directly informed treatment in a minority of patients and was not independently associated with better survival.

2018 JAMA